TITLE

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants

AUTHOR(S)
Volk, Jonathan E; Hessol, Nancy A; Gray, Glenda E; Kublin, James G; Churchyard, Gavin J; Mlisana, Koleka; Nchabeleng, Maphoshane; Buchbinder, Susan P; Bekker, Linda-Gail
PUB. DATE
April 2014
SOURCE
International Journal of STD & AIDS;Apr2014, Vol. 25 Issue 5, p332
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
By comparing younger to older participants enrolled in a HIV vaccine efficacy trial, we aimed to gain insights into the inclusion of adolescents in future trials. This was a sub-analysis of a multisite HIV vaccine randomized clinical trial in South Africa, conducted January–September 2007. Motivations for trial enrolment, social harms, adverse events and loss to follow-up were compared between younger (18–20 years old) and older participants (21–35 years old). Both younger (n = 238) and older participants (n = 563) were equally likely to report enrolling for altruistic reasons. Younger females were less likely than older participants to join for trial reimbursement (p = 0.005), while younger males were more likely to enrol because the vaccine may provide protection from HIV-acquisition (p < 0.001). There were no significant differences in the number of social harms reported. Compared to males over 20 years old, 18–20-year-old females were less likely to experience adverse events (OR = 0.1, CI 0.01–0.80) and no more likely to be lost to follow-up (OR = 0.7, CI 0.39–1.25), while 18–20-year-old males were no more likely to experience adverse events (OR = 1.3, CI 0.58–2.83) or loss to follow-up (OR = 0.8, CI 0.51–1.41). Our data support the inclusion of younger participants who are at risk for HIV in future HIV vaccine efficacy trials.
ACCESSION #
95097440

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics